UNITED
	STATES
	SECURITIES
	AND EXCHANGE COMMISSION
	WASHINGTON,
	D.C. 20549
	FORM
	8-K
	CURRENT
	REPORT
	Pursuant
	to Section 13 or 15(d) of the Securities Exchange Act of 1934
	Date
	of Report (Date of earliest event reported):  September 7,
	2010
	ENTREMED,
	INC.
	(Exact
	Name of Registrant as Specified in its Charter)
| 
 
	DELAWARE
 
	(State
	or other jurisdiction  of
 
	incorporation
	or organization)
 
 | 
 
	0-20713
 
	(Commission
	File Number)
 
 | 
 
	58-1959440
 
	(IRS
	Employer Identification
	No.)
 
 | 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	9640
	Medical Center Drive
	Rockville,
	Maryland
	(Address
	of principal executive offices)
	20850
	(Zip
	Code)
	(240)
	864-2600
	(Registrant’s
	telephone number, including area code)
	Not
	Applicable
	(Former
	name or former address, if changed since last report)
	Check the
	appropriate box below if the Form 8-K filing is intended to simultaneously
	satisfy the filing obligation of the registrant under any of the following
	provisions:
	 
| 
 
	o
 
 | 
 
	Written communications pursuant
	to Rule 425 under the Securities Act (17 CFR
	230.425)
 
 | 
 
	 
| 
 
	o
 
 | 
 
	Soliciting material pursuant to
	Rule 14a-12 under the Exchange Act (17 CFR
	240.14a-12)
 
 | 
 
	 
| 
 
	o
 
 | 
 
	Pre-commencement communications
	pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
	240.14d-2(b))
 
 | 
 
	 
| 
 
	o
 
 | 
 
	Pre-commencement communications
	pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
	240.13e-4(c))
 
 | 
 
	Item
	1.01.  Entry Into a Material Definitive Agreement.
	Offering
	of Common Stock and Warrants to Purchase Common Stock
	On
	September 8, 2010, EntreMed, Inc., a Delaware corporation (“EntreMed” or “the
	Company”), consummated the issuance and sale (the “Offering”)
	of  1,886,622 shares (the “Shares”) of its common stock, par value
	$0.01 per share (“Common Stock”) and warrants (“Warrants”) to purchase up to an
	aggregate of 377,327 shares of Common Stock, to certain investors (collectively,
	the “Investors”).  The Offering was made pursuant to a securities
	purchase agreement effective as of September 7, 2010 (the “Securities Purchase
	Agreement”) between EntreMed and the Investors.   The Shares and
	Warrants were sold in units (the “Units”) consisting of one share of Common
	Stock and a Warrant to purchase 0.20 shares of Common Stock.  The
	Shares and the Warrants are immediately separable and were issued
	separately.   The Warrants have a three year term from the date
	of issuance, are exercisable at any time 181 days after the date of issuance and
	will include provisions providing for adjustments to the number of shares
	exercisable thereunder upon stock dividends, stock splits and similar
	events.
	 In
	accordance with the Securities Purchase Agreement, EntreMed issued and sold the
	Units to the Investors for an aggregate purchase price of $5,094,000, or $2.70
	per share, which price per share for the Shares represents the consolidated
	closing bid price of the Company’s stock on September 7, 2010, as reported by
	the Nasdaq Stock Market.   The exercise price of the Warrants is
	$2.825 per share.
	A copy of
	each of the form of Warrant and the form of Securities Purchase Agreement are
	filed as Exhibits 4.1 and 10.1, respectively, to this Current Report on
	Form 8-K, and are incorporated herein by reference.  The
	foregoing description of each of the Securities Purchase Agreement and Warrant
	are a summary only and are subject to, and qualified in their entirety by, such
	exhibits.
	EntreMed
	made the Offering pursuant to a shelf registration statement on Form S-3
	(Registration No. 333-161100) previously filed and declared effective by the
	Securities and Exchange Commission (the “Commission”) on October 9, 2009, and a
	base prospectus dated as of the same date, as supplemented by a prospectus
	supplement filed with the Commission on September 8, 2010.
	In
	connection with the financing and pursuant to the Securities Purchase Agreement,
	the Investors were collectively offered the right to designate one director to
	the Company’s Board of Directors, and the director nominee,  if
	selected, will be identified by SVT (as defined below) and submitted to EntreMed
	for  approval and election to EntreMed’s Board of
	Directors.  No director has been selected by SVT at this
	time.
	We have
	agreed to pay to BroadOak Capital Partners, LLC (“BroadOak”), the advisor to the
	Investors, an aggregate fee, on behalf of the Investors, equal to 5% of the
	gross proceeds from the sale of the units in this offering, or
	$254,700.   The aggregate net proceeds from the Offering, after
	deducting the fees due to BroadOak and estimated other offering expenses payable
	by EntreMed, is expected to be approximately $4.7 million.
	China
	Rights Agreement
	Concurrently with the Offering, on
	September 7, 2010, the Company entered into a rights agreement with Selected
	Value Therapeutics I, LLC, a Delaware limited liability company
	(“SVT”) and an entity in which the purchasers have an interest, pursuant to
	which SVT has an option to exercise, on behalf of the investors, certain
	license, development and commercialization rights for the Company's lead product
	candidate, ENMD-2076, in China.  If the option is exercised, EntreMed
	will be entitled to receive development milestone payments and royalties on
	future product sales within the geographic market.   The option
	is exercisable at any time until December 31, 2011.
	On
	September 8, 2010, EntreMed issued a press release announcing the Offering
	and  the entry into the China Rights Agreement with SVT, the text of
	which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
	incorporated herein by reference.  A copy of the legal opinion of
	Arnold & Porter LLP relating to the securities issued in the Offering is
	attached as Exhibit 5.1 to this Current Report on Form 8-K.
	Item 8.01  Other
	Information
	.
	As previously reported on a Current
	Report on Form 8-K filed with the Commission on August 20, 2010, the Company
	received a letter on August 17, 2010 from the Listing Qualifications Department
	 of the Nasdaq  Stock Market  indicating that the Company was
	currently not in compliance with the minimum $35 million minimum market value of
	listed securities requirement for continued  listing on The
	NASDAQ Capital Market under Rule 5550(b)(2).  Pursuant to the terms of
	the letter, the Company was provided with 180 days, or until February 14, 2011,
	to regain compliance with the rule.  During this period,
	compliance will be regained if the market value of the Company's
	 listed securities closes at $35 million or more for a minimum  of 10
	consecutive business days, or if the Company satisfies one of the other
	continued listing requirements under Rule 5550(b).
	As of the
	date of this Current Report on Form 8-K, as a result of the consummation of
	the Offering described above, the Company believes that it has regained
	compliance with the Nasdaq Stock Market stockholders’ equity continued listing
	requirement under Rule 5550.  The Company acknowledges that Nasdaq
	will continue to monitor its ongoing compliance with the stockholders’ equity
	requirement and, if at the time of the Company’s next periodic report it does
	not evidence compliance, that it may be subject to delisting.
	Item
	9.01.  Financial Statements and Exhibits.
| 
	 
 | 
 
	Exhibit
 
	Number
 
 | 
	 
 | 
 
	Description
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	4.1
 
 | 
	 
 | 
 
	Form
	of Common Stock Purchase Warrant
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	5.1
 
 | 
	 
 | 
 
	Opinion
	of Arnold & Porter LLP
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	10.1
 
 | 
	 
 | 
 
	Form
	of Securities Purchase Agreement, by and among the Company and the
	purchasers party thereto, dated September 7, 2010
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	23.1
 
 | 
	 
 | 
 
	Consent
	of Arnold & Porter LLP (included as part of Exhibit
	5.1)
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	99.1
 
 | 
	 
 | 
 
	Press
	release dated September 8,
	2010
 
 | 
 
 
 
	SIGNATURES
	Pursuant
	to the requirements of the Securities Exchange Act of 1934, the registrant has
	duly caused this report to be signed on its behalf by the undersigned hereunto
	duly authorized.
| 
	 
 | 
 
	ENTREMED,
	INC.
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	/s/ Cynthia W. Hu
 
 | 
	 
 | 
| 
	 
 | 
 
	Name:
 
 | 
 
	Cynthia
	W. Hu
 
 | 
	 
 | 
| 
	 
 | 
 
	Title:
 
 | 
 
	Chief
	Operating Officer, General Counsel &
	Secretary
 
 | 
 
 
	Date:  September
	10, 2010
	 
	 
	Exhibit
	Index
| 
	 
 | 
 
	Exhibit
 
	Number
 
 | 
	 
 | 
 
	Description
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	4.1
 
 | 
	 
 | 
 
	Form
	of Common Stock Purchase Warrant
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	5.1
 
 | 
	 
 | 
 
	Opinion
	of Arnold & Porter LLP
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	10.1
 
 | 
	 
 | 
 
	Form
	of Securities Purchase Agreement, by and among the Company and the
	purchasers party thereto, dated September 7, 2010
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	23.1
 
 | 
	 
 | 
 
	Consent
	of Arnold & Porter LLP (included as part of Exhibit
	5.1)
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	99.1
 
 | 
	 
 | 
 
	Press
	release dated September 8,
	2010
 
 | 
 
 
	 
	 
	FORM
	OF
	COMMON
	STOCK PURCHASE WARRANT
	ENTREMED,
	INC.
	 
| 
 
	Warrant
	Shares: [___]
 
 | 
 
	Issue
	Date: September 8, 2010
 
 | 
 
	 
	THIS
	COMMON STOCK PURCHASE WARRANT (the “
	Warrant
	”) certifies
	that, for value received,
	[Name of
	Investor]
	(the “
	Holder
	”) is entitled,
	upon the terms and subject to the limitations on exercise and the conditions
	hereinafter set forth, at any time on or after 181 days following the Issue Date
	(the “
	Initial Exercise
	Date
	”) and on or prior to the close of business on the third anniversary
	of the Initial Exercise Date (the “
	Termination Date
	”)
	but not thereafter, to subscribe for and purchase from EntreMed, Inc., a
	Delaware corporation (the “
	Company
	”), up to
	[____] shares (the “
	Warrant Shares
	”) of
	Common Stock.
	 
	Section
	1
	.             
	Definitions
	.  Capitalized
	terms used and not otherwise defined herein shall have the meanings set forth in
	that certain Securities Purchase Agreement (the “
	Purchase Agreement
	”),
	dated September 7, 2010, among the Company and the purchasers signatory
	thereto.
	 
	Section
	2
	.             
	Exercise
	.
	 
	a)           
	Exercise of
	Warrant
	.  Exercise of the purchase rights represented by this
	Warrant may be made, in whole or in part, at any time or times on or after the
	Initial Exercise Date and on or before the Termination Date by delivery to the
	Company (or such other office or agency of the Company as it may designate by
	notice in writing to the registered Holder at the address of the Holder
	appearing on the books of the Company) of a duly executed facsimile copy of the
	Notice of Exercise Form annexed hereto; and, within three (3) Trading Days of
	the date said Notice of Exercise is delivered to the Company, the Company shall
	have received payment of the aggregate Exercise Price of the shares thereby
	purchased by wire transfer or cashier’s check drawn on a United States
	bank.  Notwithstanding anything herein to the contrary, the Holder
	shall not be required to physically surrender this Warrant to the Company until
	the Holder has purchased all of the Warrant Shares available hereunder and the
	Warrant has been exercised in full, in which case, the Holder shall surrender
	this Warrant to the Company for cancellation within three (3) Trading Days of
	the date the final Notice of Exercise is delivered to the
	Company.  Partial exercises of this Warrant resulting in purchases of
	a portion of the total number of Warrant Shares available hereunder shall have
	the effect of lowering the outstanding number of Warrant Shares purchasable
	hereunder in an amount equal to the applicable number of Warrant Shares
	purchased.  The Holder and the Company shall maintain records showing
	the number of Warrant Shares purchased and the date of such
	purchases.  The Company shall deliver any objection to any Notice of
	Exercise Form within 1 Business Day of receipt of such notice.  In the
	event of any dispute or discrepancy, the records of the Holder shall be
	controlling and determinative in the absence of manifest error.
	The Holder and any assignee, by
	acceptance of this Warrant, acknowledge and agree that, by reason of the
	provisions of this paragraph, following the purchase of a portion of the Warrant
	Shares hereunder, the number of Warrant Shares available for purchase hereunder
	at any given time may be less than the amount stated on the face
	hereof.
	 
	b)           
	Exercise
	Price
	.  The exercise price per share of the Common Stock under
	this Warrant shall be $2.825, subject to adjustment hereunder (the “
	Exercise
	Price
	”).
	 
	c)           
	Mechanics of
	Exercise
	.
	 
	i.    
	  
	Delivery
	of Certificates Upon Exercise
	.  Certificates for shares
	purchased hereunder shall be transmitted by the Transfer Agent to the Holder by
	crediting the account of the Holder’s prime broker with the Depository Trust
	Company through its Deposit Withdrawal Agent Commission (“
	DWAC
	”) system if the
	Company is then a participant in such system and there is an effective
	Registration Statement permitting the issuance of the Warrant Shares to the
	Holder, and otherwise by physical delivery to the address specified by the
	Holder in the Notice of Exercise by the date that is three (3) Trading Days
	after the latest of (A) the delivery to the Company of the Notice of Exercise
	Form, (B) surrender of this Warrant (if required) and (C) payment of the
	aggregate Exercise Price as set forth above  (such date, the “
	Warrant Share Delivery
	Date
	”).  This Warrant shall be deemed to have been exercised on
	the first date on which all of the foregoing have been delivered to the
	Company.  The Warrant Shares shall be deemed to have been issued, and
	Holder or any other person so designated to be named therein shall be deemed to
	have become a holder of record of such shares for all purposes, as of the date
	the Warrant has been exercised, with payment to the Company of the Exercise
	Price and all taxes required to be paid by the Holder, if any, pursuant to
	Section 2(d)(vi) prior to the issuance of such shares, having been
	paid.
	 
	ii.      
	Delivery of New Warrants
	Upon Exercise
	.  If this Warrant shall have been exercised in
	part, the Company shall, at the request of a Holder and upon surrender of this
	Warrant certificate, at the time of delivery of the certificate or certificates
	representing Warrant Shares, deliver to Holder a new Warrant evidencing the
	rights of Holder to purchase the unpurchased Warrant Shares called for by this
	Warrant, which new Warrant shall in all other respects be identical with this
	Warrant.
	 
	iii.     
	No Fractional Shares or
	Scrip
	.  No fractional shares or scrip representing fractional
	shares shall be issued upon the exercise of this Warrant.  As to any
	fraction of a share which the Holder would otherwise be entitled to purchase
	upon such exercise, the Company shall, at its election, either pay a cash
	adjustment in respect of such final fraction in an amount equal to such fraction
	multiplied by the Exercise Price or round up to the next whole
	share.
	 
	iv.     
	Charges, Taxes and
	Expenses
	.  Issuance of certificates for Warrant Shares shall be
	made without charge to the Holder for any issue or transfer tax or other
	incidental expense in respect of the issuance of such certificate, all of which
	taxes and expenses shall be paid by the Company, and such certificates shall be
	issued in the name of the Holder or in such name or names as may be directed by
	the Holder;
	provided
	,
	however
	, that in the
	event certificates for Warrant Shares are to be issued in a name other than the
	name of the Holder, this Warrant when surrendered for exercise shall be
	accompanied by the Assignment Form attached hereto duly executed by the Holder
	and the Company may require, as a condition thereto, the payment of a sum
	sufficient to reimburse it for any transfer tax incidental thereto.
	 
	v.      
	Closing of
	Books
	.  The Company will not close its stockholder books or
	records in any manner which prevents the timely exercise of this Warrant,
	pursuant to the terms hereof.
	 
	Section
	3
	.             
	Certain
	Adjustments
	.
	 
	a)           
	Stock Dividends and
	Splits
	. If the Company, at any time while this Warrant is outstanding:
	(i) pays a stock dividend or otherwise makes a distribution or distributions on
	shares of its Common Stock or any other equity or equity equivalent securities
	payable in shares of Common Stock (which, for avoidance of doubt, shall not
	include any shares of Common Stock issued by the Company upon exercise of this
	Warrant), (ii) subdivides outstanding shares of Common Stock into a larger
	number of shares, (iii) combines (including by way of reverse stock split)
	outstanding shares of Common Stock into a smaller number of shares, or (iv)
	issues by reclassification of shares of the Common Stock any shares of capital
	stock of the Company, then in each case the Exercise Price shall be multiplied
	by a fraction of which the numerator shall be the number of shares of Common
	Stock (excluding treasury shares, if any) outstanding immediately before such
	event and of which the denominator shall be the number of shares of Common Stock
	outstanding immediately after such event, and the number of shares issuable upon
	exercise of this Warrant shall be proportionately adjusted such that the
	aggregate Exercise Price of this Warrant shall remain unchanged.  Any
	adjustment made pursuant to this Section 3(a) shall become effective immediately
	after the record date for the determination of stockholders entitled to receive
	such dividend or distribution and shall become effective immediately after the
	effective date in the case of a subdivision, combination or
	re-classification.
	 
	b)           
	Calculations
	. All
	calculations under this Section 3 shall be made to the nearest cent or the
	nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
	the number of shares of Common Stock deemed to be issued and outstanding as of a
	given date shall be the sum of the number of shares of Common Stock (excluding
	treasury shares, if any) issued and outstanding.
	 
	c)           
	Notice to
	Holder
	.
	 
	i.     
	 
	Adjustment to
	Exercise Price
	. Whenever the Exercise Price is adjusted pursuant to this
	Section 3, the Company shall promptly mail to the Holder a notice setting forth
	the Exercise Price after such adjustment and setting forth a brief statement of
	the facts requiring such adjustment.
	 
	ii.      
	Notice to Allow Exercise by
	Holder
	. If (A) the Company shall declare a dividend (or any other
	distribution in whatever form) on the Common Stock, (B) the Company shall
	declare a special nonrecurring cash dividend on or a redemption of the Common
	Stock, (C) the Company shall authorize the granting to all holders of the Common
	Stock rights or warrants to subscribe for or purchase any shares of capital
	stock of any class or of any rights, (D) the approval of any stockholders of the
	Company shall be required in connection with any reclassification of the Common
	Stock, any consolidation or merger to which the Company is a party, any sale or
	transfer of all or substantially all of the assets of the Company, or any
	compulsory share exchange whereby the Common Stock is converted into other
	securities, cash or property, or (E) the Company shall authorize the voluntary
	or involuntary dissolution, liquidation or winding up of the affairs of the
	Company, then, in each case, the Company shall cause to be mailed to the Holder
	at its last address as it shall appear upon the Warrant Register of the Company,
	concurrently with any notice provided to holders of the Company’s Common Stock
	or filed with the Commission, a notice stating (x) the date on which a record is
	to be taken for the purpose of such dividend, distribution, redemption, rights
	or warrants, or if a record is not to be taken, the date as of which the holders
	of the Common Stock of record to be entitled to such dividend, distributions,
	redemption, rights or warrants are to be determined or (y) the date on which
	such reclassification, consolidation, merger, sale, transfer or share exchange
	is expected to become effective or close, and the date as of which it is
	expected that holders of the Common Stock of record shall be entitled to
	exchange their shares of the Common Stock for securities, cash or other property
	deliverable upon such reclassification, consolidation, merger, sale, transfer or
	share exchange; provided that the failure to mail such notice or any defect
	therein or in the mailing thereof shall not affect the validity of the corporate
	action required to be specified in such notice. The Holder shall remain entitled
	to exercise this Warrant during the period commencing on the date of such notice
	to the effective date of the event triggering such notice except as may
	otherwise be expressly set forth herein.
	 
	Section
	4
	.            
	Transfer of
	Warrant
	.
	 
	a)           
	Transferability
	.  This
	Warrant and all rights hereunder are transferable, in whole or in part, upon
	surrender of this Warrant at the principal office of the Company or its
	designated agent, together with (i) a written assignment of this Warrant
	substantially in the form attached hereto duly executed by the Holder or its
	agent or attorney and funds sufficient to pay any transfer taxes payable upon
	the making of such transfer and (ii) any other documents or certificates
	reasonably requested by the Company to effect such transfer.  Upon
	such surrender and, if required, such payment, the Company shall execute and
	deliver a new Warrant or Warrants in the name of the assignee or assignees, as
	applicable, and in the denomination or denominations specified in such
	instrument of assignment, and shall issue to the assignor a new Warrant
	evidencing the portion of this Warrant not so assigned, and this Warrant shall
	promptly be cancelled.  The Warrant, if properly assigned in
	accordance herewith, may be exercised by a new holder for the purchase of
	Warrant Shares without having a new Warrant issued.
	 
	b)           
	New Warrants
	. This
	Warrant may be divided or combined with other Warrants upon presentation hereof
	at the aforesaid office of the Company, together with a written notice
	specifying the names and denominations in which new Warrants are to be issued,
	signed by the Holder or its agent or attorney.  Subject to compliance
	with Section 4(a), as to any transfer which may be involved in such division or
	combination, the Company shall execute and deliver a new Warrant or Warrants in
	exchange for the Warrant or Warrants to be divided or combined in accordance
	with such notice. All Warrants issued on transfers or exchanges shall be dated
	the initial issuance date set forth on the first page of this Warrant and shall
	be identical with this Warrant except as to the number of Warrant Shares
	issuable pursuant thereto.
	 
	c)           
	Warrant Register
	. The
	Company shall register this Warrant, upon records to be maintained by the
	Company for that purpose (the “
	Warrant Register
	”),
	in the name of the record Holder hereof from time to time.  The
	Company may deem and treat the registered Holder of this Warrant as the absolute
	owner hereof for the purpose of any exercise hereof or any distribution to the
	Holder, and for all other purposes, absent actual notice to the
	contrary.
	 
	Section
	5
	.             
	Miscellaneous
	.
	 
	a)           
	No Rights as Stockholder
	Until Exercise
	.  This Warrant does not entitle the Holder to
	any voting rights, dividends or other rights as a stockholder of the Company
	prior to the exercise hereof as set forth in Section 2.
	 
	b)           
	Loss, Theft, Destruction or
	Mutilation of Warrant
	. The Company covenants that upon receipt by the
	Company of evidence reasonably satisfactory to it of the loss, theft,
	destruction or mutilation of this Warrant or any stock certificate relating to
	the Warrant Shares, and in case of loss, theft or destruction, of indemnity or
	security reasonably satisfactory to it (which, in the case of the Warrant, shall
	not include the posting of any bond), and upon surrender and cancellation of
	such Warrant or stock certificate, if mutilated, the Company will make and
	deliver a new Warrant or stock certificate of like tenor and dated as of such
	cancellation, in lieu of such Warrant or stock certificate.
	 
	c)           
	Saturdays, Sundays,
	Holidays, etc
	.  If the last or appointed day for the taking of
	any action or the expiration of any right required or granted herein shall not
	be a Business Day, then, such action may be taken or such right may be exercised
	on the next succeeding Business Day.
	 
	d)           
	Authorized Shares;
	Noncircumvention
	.
	 
	The
	Company covenants that, during the period the Warrant is outstanding, it will
	reserve from its authorized and unissued Common Stock a sufficient number of
	shares to provide for the issuance of the Warrant Shares upon the exercise of
	any purchase rights under this Warrant.  The Company further covenants
	that its issuance of this Warrant shall constitute full authority to its
	officers who are charged with the duty of executing stock certificates to
	execute and issue the necessary certificates for the Warrant Shares upon the
	exercise of the purchase rights under this Warrant.  The Company will
	take all such reasonable action as may be necessary to assure that such Warrant
	Shares may be issued as provided herein without violation of any applicable law
	or regulation, or of any requirements of the Trading Market upon which the
	Common Stock may be listed.  The Company covenants that all Warrant
	Shares which may be issued upon the exercise of the purchase rights represented
	by this Warrant will, upon exercise of the purchase rights represented by this
	Warrant and payment for such Warrant Shares in accordance herewith, be duly
	authorized, validly issued, fully paid and nonassessable.
	 
	Except
	and to the extent as waived or consented to by the Holder, the Company shall not
	by any action, including, without limitation, amending its certificate of
	incorporation or through any reorganization, transfer of assets, consolidation,
	merger, dissolution, issue or sale of securities or any other voluntary action,
	avoid or seek to avoid the observance or performance of any of the terms of this
	Warrant, but will at all times in good faith assist in the carrying out of all
	such terms and in the taking of all such actions as may be necessary or
	appropriate to protect the rights of Holder as set forth in this Warrant against
	impairment.  Without limiting the generality of the foregoing, the
	Company will (i) not increase the par value of any Warrant Shares above the
	amount payable therefor upon such exercise immediately prior to such increase in
	par value, (ii) take all such action as may be necessary or appropriate in order
	that the Company may validly and legally issue fully paid and nonassessable
	Warrant Shares upon the exercise of this Warrant and (iii) use commercially
	reasonable efforts to obtain all such authorizations, exemptions or consents
	from any public regulatory body having jurisdiction thereof, as may be,
	necessary to enable the Company to perform its obligations under this
	Warrant.
	 
	Before
	taking any action which would result in an adjustment in the number of Warrant
	Shares for which this Warrant is exercisable or in the Exercise Price, the
	Company shall obtain all such authorizations or exemptions thereof, or consents
	thereto, as may be necessary from any public regulatory body or bodies having
	jurisdiction thereof.
	 
	e)           
	Jurisdiction
	. All
	questions concerning the construction, validity, enforcement and interpretation
	of this Warrant shall be determined in accordance with the provisions of the
	Purchase Agreement.
	 
	f)           
	Nonwaiver and
	Expenses
	.  No course of dealing or any delay or failure to
	exercise any right hereunder on the part of Holder shall operate as a waiver of
	such right or otherwise prejudice Holder’s rights, powers or
	remedies.
	 
	g)           
	Notices
	.  Any
	notice, request or other document required or permitted to be given or delivered
	to the Holder by the Company shall be delivered in accordance with the notice
	provisions of the Purchase Agreement.
	 
	h)           
	Remedies
	.  The
	Holder, in addition to being entitled to exercise all rights granted by law,
	including recovery of damages, will be entitled to specific performance of its
	rights under this Warrant.  The Company agrees that monetary damages
	would not be adequate compensation for any loss incurred by reason of a breach
	by it of the provisions of this Warrant and hereby agrees to waive and not to
	assert the defense in any action for specific performance that a remedy at law
	would be adequate.
	 
	i)           
	Successors and
	Assigns
	.  Subject to applicable securities laws, this Warrant
	and the rights and obligations evidenced hereby shall inure to the benefit of
	and be binding upon the successors and permitted assigns of the Company and the
	successors and permitted assigns of Holder.  The provisions of this
	Warrant are intended to be for the benefit of any Holder from time to time of
	this Warrant and shall be enforceable by the Holder or holder of Warrant
	Shares.
	 
	j)         
	  
	Amendment
	.  This
	Warrant may be modified or amended or the provisions hereof waived with the
	written consent of the Company and the Holder.
	 
	k)           
	Severability
	.  Wherever
	possible, each provision of this Warrant shall be interpreted in such manner as
	to be effective and valid under applicable law, but if any provision of this
	Warrant shall be prohibited by or invalid under applicable law, such provision
	shall be ineffective to the extent of such prohibition or invalidity, without
	invalidating the remainder of such provisions or the remaining provisions of
	this Warrant.
	 
	l)         
	  
	Headings
	.  The
	headings used in this Warrant are for the convenience of reference only and
	shall not, for any purpose, be deemed a part of this Warrant.
	********************
	(Signature
	Pages Follow)
	 
	  
	IN
	WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
	officer thereunto duly authorized as of the date first above
	indicated.
	  
| 
	 
 | 
 
	ENTREMED,
	INC.
 
 | 
| 
	 
 | 
	 
 | 
	 
 | 
| 
	 
 | 
 
	By:
 
 | 
	 
 | 
| 
	 
 | 
	 
 | 
 
	Name:  Michael
	M. Tarnow
 
 | 
| 
	 
 | 
	 
 | 
 
	Title:
	Executive Chairman
 
 | 
 
 
 
	 
	 
	NOTICE
	OF EXERCISE
	TO:           ENTREMED,
	INC.
	(1)
	  The undersigned
	hereby elects to purchase ________ Warrant Shares of the Company pursuant to the
	terms of the attached Warrant (only if exercised in full), and tenders herewith
	payment of the exercise price in full, together with all applicable transfer
	taxes, if any.  Payment shall take the form of  in lawful
	money of the United States, by wire transfer of immediately available funds or
	by check.
	 
	(2)
	  Please issue a
	certificate or certificates representing said Warrant Shares in the name of the
	undersigned or in such other name as is specified below:
	 
	                                                   ________________________________________                                                          
	The
	Warrant Shares shall be delivered to the following DWAC Account Number or by
	physical delivery of a certificate to:
	 
	                                                   ________________________________________
	 
	                                                   ________________________________________
	 
	                                                   ________________________________________ 
	 
 
	[SIGNATURE
	OF HOLDER]
	 
	Name of
	Investing Entity:
	___________________________________________________________________________
	Signature of Authorized Signatory of
	Investing Entity
	:
	_____________________________________________________
	Name of
	Authorized Signatory:
	_______________________________________________________________________
	Title of
	Authorized Signatory:
	________________________________________________________________________
	Date:
	__________________________________________________________________________________________
	 
	 
	ASSIGNMENT
	FORM
	(To
	assign the foregoing warrant, execute
	this form
	and supply required information.
	Do not
	use this form to exercise the warrant.)
	FOR VALUE
	RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all
	rights evidenced thereby are hereby assigned to
| 
	________________________________________________________
	whose
	address is
 | 
| 
	 
 | 
| 
	______________________________________________________________
	.
 | 
| 
	 
 | 
	 
 | 
| 
	____________________________________________________________________ 
 | 
 
 
 
 
| 
	 
 | 
 
	Dated:  ______________,
	_______
 
 | 
| 
	 
 | 
	 
 | 
| 
	 
 | 
 
	Holder’s
	Signature:   _______________________________
 
 | 
| 
	 
 | 
	 
 | 
| 
	 
 | 
 
	Holder’s
	Address:   
	 _______________________________
 
 | 
| 
	 
 | 
	 
 | 
| 
	 
 | 
	                                 
	_______________________________ 
 | 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 
	Signature
	Guaranteed:   
	___________________________________________
 
	NOTE:  The
	signature to this Assignment Form must correspond with the name as it appears on
	the face of the Warrant, without alteration or enlargement or any change
	whatsoever, and must be guaranteed by a bank or trust
	company.  Officers of corporations and those acting in a fiduciary or
	other representative capacity should file proper evidence of authority to assign
	the foregoing Warrant.
	Exhibit
	5.1
	[Arnold
	& Porter LLP Letterhead]
	September
	8, 2010
	EntreMed,
	Inc.
	9640
	Medical Center Drive
	Rockville,
	MD  20850
	Ladies
	and Gentlemen:
	We have
	acted as special counsel to EntreMed, Inc., a Delaware corporation (the “
	Company
	”), in
	connection with the offering by the Company of 1,886,662 shares of the Company’s
	common stock, par value $0.01 per share (the “
	Shares
	”) and 377,327
	warrants to purchase common stock of the Company (each, a “
	Warrant
	” and
	together, the “
	Warrants
	”, and
	together with the Shares, the “
	Securities
	”),
	pursuant to (i) the Registration Statement on Form S-3 (file
	no. 333-161100), which was declared effective by the Securities and
	Exchange Commission (the “
	Commission
	”) on
	October 9, 2009 (the “
	Registration
	Statement
	”) under the Securities Act of 1933, as amended (the “
	Securities Act
	”), the
	base Prospectus dated October 9, 2009 and the related Prospectus Supplement to
	be filed with the Commission (together with the base Prospectus, the “
	Prospectus
	Supplement
	”); (ii) the securities purchase agreement dated as of
	September 7, 2010 (the “
	Securities Purchase
	Agreement
	”) between the Company and the purchasers (each, a “
	Purchaser
	” and
	collectively, the “
	Purchasers”
	) to be
	filed by the Company as Exhibit 10.1 to its Current Report on Form 8-K
	on or about September 10, 2010 (the “
	Form 8-K
	”); and
	(iii) the form of Warrant to be filed by the Company as Exhibit 4.1 to the Form
	8-K.  This opinion letter is furnished to you at your request to
	enable you to fulfill the requirements of Item 601(b)(5) of
	Regulation S-K, 17 C.F.R.  § 229.601(b)(5), in
	connection with the Registration Statement.
	 
	For
	purposes of this opinion letter, we have examined originals or copies, certified
	or otherwise identified to our satisfaction, of such agreements, corporate
	records, instruments and other documents as we have deemed necessary or
	appropriate for the purpose of rendering the opinions hereinafter
	expressed.  In our examination of the aforesaid documents, we have
	assumed the genuineness of all signatures, the legal capacity of all natural
	persons, the accuracy and completeness of all documents submitted to us, the
	authenticity of all original documents, and the conformity to authentic original
	documents of all documents submitted to us as copies (including
	telecopies).   As to all matters of fact, we have relied on the
	representations and statements of fact made in the documents so reviewed, and we
	have not independently established the facts so relied on.  This
	opinion letter is given, and all statements herein are made, in the context of
	the foregoing.
	 
	This
	opinion letter is based as to matters of law solely on the Delaware General
	Corporation Law, as amended.  We express no opinion herein as to any
	other laws, statutes, ordinances, rules or regulations.  As used
	herein, the term “Delaware General Corporation Law, as amended” includes the
	statutory provisions contained therein, all applicable provisions of the
	Delaware Constitution and reported judicial decisions interpreting these
	laws.
	 
	Based
	upon, subject to and limited by the foregoing and the further assumptions,
	qualifications and limitations set forth herein, we are of the opinion that,
	when the Securities are issued and delivered to the Purchasers upon the terms
	and subject to the conditions set forth in, and in the manner contemplated by,
	the Securities Purchase Agreement and the Prospectus Supplement and against
	receipt by the Company of the consideration therefor as provided therein, (i)
	the Shares will be validly issued, fully paid and nonassessable and the Warrants
	shall be validly issued, and (ii) upon the exercise and payment of the
	consideration as set forth therein, the shares of common stock issuable upon
	exercise of the Warrants will be validly issued, fully paid and
	nonassessable.
	 
	The
	opinion expressed herein is based upon the assumption that there will be no
	material changes in the documents examined and matters investigated and that at
	the time of issuance of the Shares there will be authorized but unissued shares
	of common stock of the Company available in amounts sufficient for such
	issuance.
	 
	This
	opinion letter has been prepared for use in connection with the Registration
	Statement.  This opinion speaks as of today’s date and is limited to
	present statutes, regulations and judicial interpretations.  In
	rendering this opinion, we assume no obligation to revise or supplement this
	opinion should present laws, regulations or judicial interpretations be changed
	by legislative or regulatory action, judicial decision or
	otherwise.  This opinion is limited to the matters expressly set forth
	herein, and no other opinion should be inferred beyond such
	matters.
	 
	We hereby
	consent to the filing of this opinion letter as Exhibit 5.1 to the Form
	8-K, and to the reference to this firm under the caption “Legal Matters” in the
	Prospectus Supplement.  By giving such consent we do not thereby admit
	that we are within the category of persons whose consent is required under
	Section 7 of the Securities Act, or the rules and regulations of the
	Commission thereunder.
	 
	This
	opinion is rendered solely to you in connection with the above matter. This
	opinion may not be relied upon by you for any other purpose or relied upon by or
	furnished to any other person without our prior written consent.
	 
	Very
	truly yours,
	/s/
	Arnold & Porter LLP
	 
	 
	SECURITIES
	PURCHASE AGREEMENT
 
	 
	This
	Securities Purchase Agreement (this “
	Agreement
	”) is dated
	as of September 7, 2010, between EntreMed, Inc., a Delaware corporation (the
	“
	Company
	”), and
	each purchaser identified on the signature pages hereto (each, including its
	successors and assigns, a “
	Purchaser
	” and
	collectively the “
	Purchasers
	”).
	 
	WHEREAS,
	subject to the terms and conditions set forth in this Agreement and pursuant to
	an effective registration statement under the Securities Act of 1933, as amended
	(the “
	Securities
	Act
	”), the Company desires to issue and sell to each Purchaser, and each
	Purchaser, severally and not jointly, desires to purchase from the Company,
	securities of the Company as more fully described in this
	Agreement.
	 
	NOW,
	THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement,
	and for other good and valuable consideration the receipt and adequacy of which
	are hereby acknowledged, the Company and each Purchaser agree as
	follows:
	 
	ARTICLE
	I.
	DEFINITIONS
	 
	1.1
	           
	Definitions
	.  In addition to the terms defined elsewhere in
	this Agreement, for all purposes of this Agreement, the following terms have the
	meanings set forth in this Section 1.1:
	 
	“
	Business Day
	” means
	any day except any Saturday, any Sunday, any day which is a federal legal
	holiday in the United States or any day on which banking institutions in the
	State of New York are authorized or required by law or other governmental action
	to close.
	 
	“
	Closing
	” means the
	closing of the purchase and sale of the Securities pursuant to Section
	2.1.
	 
	“
	Closing Date
	” means
	the Trading Day on which all of the Transaction Documents have been executed and
	delivered by the applicable parties thereto, and all conditions precedent to (i)
	the Purchasers’ obligations to pay the Subscription Amount and (ii) the
	Company’s obligations to deliver the Securities, in each case, have been
	satisfied or waived, but in no event later than the third Trading Day following
	the date hereof.
	 
	 “
	Commission
	” means the
	United States Securities and Exchange Commission.
	 
	“
	Common Stock
	” means
	the common stock of the Company, par value $0.01 per share, and any other class
	of securities into which such securities may hereafter be reclassified or
	changed.
	 
	“
	Per Share Purchase
	Price
	” equals $2.70, subject to adjustment for reverse and forward stock
	splits, stock dividends, stock combinations and other similar transactions of
	the Common Stock that occur after the date of this Agreement.
	 
	“
	Person
	” means an
	individual or corporation, partnership, trust, incorporated or unincorporated
	association, joint venture, limited liability company, joint stock company,
	government (or an agency or subdivision thereof) or other entity of any
	kind.
	 
	 “
	Prospectus
	” means the
	final prospectus filed for the Registration Statement.
	 
	“
	Prospectus
	Supplement
	” means the supplement to the Prospectus complying with Rule
	424(b) of the Securities Act that is filed with the Commission and delivered by
	the Company to each Purchaser at the Closing.
	 
	 
	“
	Registration
	Statement
	” means the effective registration statement with Commission
	file No. 333-161100 which registers the sale of the Shares, the Warrants and the
	Warrant Shares by the Purchasers.
	 
	“
	Rule 424
	” means Rule
	424 promulgated by the Commission pursuant to the Securities Act, as such Rule
	may be amended or interpreted from time to time, or any similar rule or
	regulation hereafter adopted by the Commission having substantially the same
	purpose and effect as such Rule.
	 
	“
	Securities
	” means the
	Shares, the Warrants and the Warrant Shares.
	 
	“
	Shares
	” means the
	shares of Common Stock issued or issuable to each Purchaser pursuant to this
	Agreement.
	 
	“
	Subscription Amount
	”
	means, as to each Purchaser, the aggregate amount to be paid for Shares and
	Warrants purchased hereunder as specified below such Purchaser’s name on the
	signature page of this Agreement and next to the heading “Subscription Amount,”
	in United States dollars and in immediately available funds.
	 
	 “
	Trading Day
	” means a
	day on which the principal Trading Market is open for trading.
	 
	“
	Trading Market
	” means
	any of the following markets or exchanges on which the Common Stock is listed or
	quoted for trading on the date in question: the Nasdaq Capital Market, the
	Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE AMEX or the New
	York Stock Exchange (or any successors to any of the foregoing).
	 
	“
	Transaction
	Documents
	” means this Agreement, the Warrants and any other documents or
	agreements executed in connection with the transactions contemplated
	hereunder.
	 
	“
	Transfer Agent
	” means
	American Stock Transfer & Trust Company, the current transfer agent of the
	Company, and any successor transfer agent of the Company.
	 
	 “
	Warrants
	” means,
	collectively, the Common Stock purchase warrants delivered to the Purchasers at
	the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be
	exercisable 181 days from the date hereof and have a term of exercise equal to
	three years from the date of exercise, in the form of
	Exhibit A
	attached
	hereto.
	 
	“
	Warrant Shares
	” means
	the shares of Common Stock issuable upon exercise of the Warrants.
	 
	ARTICLE
	II.
	PURCHASE
	AND SALE
	 
	2.1
	           
	Closing
	.  On
	the Closing Date, upon the terms and subject to the conditions set forth herein,
	substantially concurrent with the execution and delivery of this Agreement by
	the parties hereto, the Company agrees to sell, and the Purchasers, severally
	and not jointly, agree to purchase, up to an aggregate of $5,100,000 of Shares
	and Warrants.  The Shares and Warrants will be sold together as units,
	each unit consisting of one shares of Common Stock and a Warrant to purchase
	0.20 shares of Common Stock.  Each Purchaser shall deliver to the
	Company, via wire transfer of immediately available funds, the amount equal to
	such Purchaser’s Subscription Amount as set forth on the signature page hereto
	executed by such Purchaser and the Company shall deliver to each Purchaser its
	respective Shares and a Warrant as determined pursuant to Section 2.2(a), and
	the Company and each Purchaser shall deliver the other items set forth in
	Section 2.2 deliverable at the Closing.  Upon satisfaction of the
	covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall
	occur at 10:00 a.m. at the offices of Arnold & Porter LLP, 555 Twelfth
	Street, N.W., Washington, D.C. 20005 or such other location as the parties shall
	mutually agree.
	 
	 
	2.2
	           
	Deliveries
	.
	 
	(a)
	           On
	or prior to the Closing Date, the Company shall deliver or cause to be delivered
	to each Purchaser the following:
	 
	(i)
	           this
	Agreement duly executed by the Company;
	 
	(ii)
	          a
	Warrant registered in the name of such Purchaser to purchase the number of
	shares of Common Stock set forth in such Warrant, with an exercise price equal
	to $2.825 subject to adjustment therein (such Warrant certificate may be
	delivered within three Trading Days of the Closing Date); and
	 
	(iii)
	         the
	Prospectus and Prospectus Supplement (which may be delivered in accordance with
	Rule 172 under the Securities Act).
	 
	(b)
	           On
	or prior to the Closing Date, each Purchaser shall deliver or cause to be
	delivered to the Company the following:
	 
	(i)
	           this
	Agreement duly executed by such Purchaser; and
	 
	(ii)
	        
	 such Purchaser’s Subscription Amount by wire transfer to the account as
	specified in writing by the Company or by delivery of immediately available
	funds.
	 
	2.3
	           
	Closing
	Conditions
	.
	 
	(a)           The
	obligations of the Company hereunder in connection with the Closing are subject
	to the following conditions being met:
	 
	(i)
	           the
	accuracy in all material respects on the Closing Date of the representations and
	warranties of the Purchasers contained herein (unless as of a specific date
	therein);
	 
	(ii)
	          all
	obligations, covenants and agreements of each Purchaser required to be performed
	at or prior to the Closing Date shall have been performed; and
	 
	(iii)
	         the
	delivery by each Purchaser of the items set forth in Section 2.2(b) of this
	Agreement.
	 
	(b)
	           The
	respective obligations of the Purchasers hereunder in connection with the
	Closing are subject to the following conditions being met:
	 
	(i)
	           the
	accuracy in all material respects when made and on the Closing Date of the
	representations and warranties of the Company contained herein (unless as of a
	specific date therein);
	 
	(ii)
	          all
	obligations, covenants and agreements of the Company required to be performed at
	or prior to the Closing Date shall have been performed; and
	 
	(iii)
	         the
	delivery by the Company of the items set forth in Section 2.2(a) of this
	Agreement.
	 
	 
	ARTICLE
	III.
	REPRESENTATIONS,
	WARRANTIES AND COVENANTS
	 
	3.1
	           
	Representations and
	Warranties of the Company
	.  The Company hereby represents,
	warrants and covenants to each Purchaser as follows:
	 
	(a)
	           The
	issuance and sale of each of the Shares and the Warrants have been duly
	authorized by the Company, and the Shares, when issued and paid for in
	accordance with this Agreement, will be duly and validly issued, fully paid and
	nonassessable.  The Warrant Shares have been duly authorized and
	reserved for issuance pursuant to the terms of the Warrants, and the Warrant
	Shares, when issued by the Company upon valid exercise of the Warrants and
	payment of the exercise price, will be duly and validly issued, fully paid and
	nonassessable.
	 
	(b)
	           Each
	of this Agreement and the Warrants constitutes a valid and binding obligation of
	the Company enforceable against the Company in accordance with its
	terms,.
	 
	(c)
	           The
	Company will use its commercially reasonable efforts to maintain the
	effectiveness of the Registration Statement in accordance with the rules and
	regulations promulgated by the Commission.
	 
	(d)
	           As
	of the Closing Date, the Company shall have duly authorized and reserved for
	issuance a number of shares of Common Stock which equals the number of 
	Warrants.  The Company shall, so long as any of the Warrants are
	outstanding, take all action necessary to reserve and keep available out of its
	authorized and unissued capital stock, solely for the purpose of
	effecting the exercise of the  Warrants, all of the number of Warrant
	Shares.
	 
	(e)
	           Within
	one Business Day of the Closing, the Company shall deliver irrevocable
	instructions to the Transfer Agent instructing the Transfer Agent to deliver via
	the Depository Trust Company Deposit Withdrawal Agent Commission System (“
	DWAC
	”), of if
	requested, by physical stock certificate as soon as practicable, that number of
	Shares equal to such Purchaser’s Subscription Amount divided by the Per Share
	Purchase Price, registered in the name of such Purchaser.
	 
	3.2
	           
	Representations and
	Warranties of the Purchasers
	.  Each Purchaser, for itself and
	for no other Purchaser, hereby represents and warrants as follows:
	 
	(a)
	           Such
	Purchaser has received the Company’s base prospectus relating to the Securities
	and the prospectus supplement dated the date hereof.  Such Purchaser
	acknowledges that such Purchaser has received certain additional information
	regarding the Offering, including pricing information (the “
	Offering
	Information
	”).  Such Offering Information may be provided to
	the Purchaser by any means permitted under the Securities Act, including through
	a prospectus supplement, a free writing prospectus or oral
	communications.
	 
	(b)
	           Such
	Purchaser has full right, power, authority and capacity to enter into this
	Agreement and to consummate the transactions contemplated hereby and has taken
	all necessary action to authorize the execution, delivery and performance of
	this Agreement, and this Agreement constitutes a valid and binding obligation of
	such Purchaser enforceable against such Purchaser in accordance with its
	terms.
	 
	(c)
	           Such
	Purchaser understands that nothing in the Registration Statement, the base
	prospectus, the Offering Information and any amendments or supplements thereto,
	this Agreement or any other materials presented to such Purchaser in connection
	with the purchase and sale of the Securities constitutes legal, tax or
	investment advice.  Such Purchaser has consulted such legal, tax and
	investment advisors as it, in its sole discretion, has deemed necessary or
	appropriate in connection with its purchase of the Securities.
	 
	 
	ARTICLE
	IV.
	OTHER
	AGREEMENTS OF THE PARTIES
	 
	4.1
	           
	Board of
	Directors
	.   The Company shall use its best efforts to
	take all action necessary in accordance with the Delaware General Corporation
	Law, applicable Trading Market rules, its Certificate of Incorporation and its
	Amended and Restated Bylaws, and shall use its best efforts to take all other
	actions necessary in connection with the rights granted under this Section 4.1,
	to ensure that the Purchasers shall have the right to designate one individual
	to serve as a member of the Company’s Board of Directors (the “
	Purchaser
	Designee
	”).  The Purchaser Designee will be named by Selected
	Value Therapeutics GP, LLC and be acceptable to the Company.  In lieu
	of a board seat, Selected Value Therapeutics GP, LLC may instead elect, at its
	option, to designate an observer to the Board (the “
	Purchaser
	Observer
	”).  Such Purchaser Observer may attend, in person, as
	an observer, all meetings held in person and participate in telephonic meetings
	of the Board of Directors of the Company, provided that such Purchaser Observer
	shall not be entitled to vote on any matter brought to a vote at any such
	meeting.  The Company reserves the right to withhold any information
	and to exclude such Purchaser Observer from any meeting, or any portion thereof,
	as is reasonably determined by the Chairman of the Board or a majority of the
	members of the Board of Directors or any committee thereof (in the case of
	committee meetings) to be necessary for purposes of confidentiality, competitive
	factors, attorney-client privilege or other reasonable purposes (at the sole
	discretion of the Chairman of the Board or a majority of the members of the
	Board of Directors or a majority of the members of any committee, with respect
	to a meeting of such committee, as applicable).
	 
	4.2
	           
	Warrant
	Shares
	.  If at any time following the date hereof the
	Registration Statement (or any subsequent registration statement registering the
	exercise of the Warrant Shares) is not effective or is not otherwise available
	for the sale or resale of the Warrant Shares, the Company shall immediately
	notify the holders of the Warrants in writing that such registration statement
	is not then effective and thereafter shall promptly notify such holders when the
	registration statement is again effective.  The Company shall use
	commercially reasonable efforts to keep a registration statement (including the
	Registration Statement) registering the issuance of the Warrant Shares effective
	during the term of the Warrants.
	 
	4.3
	           
	Use of
	Proceeds
	.  The Company shall use the net proceeds from the sale
	of the Securities hereunder for working capital purposes and as set forth in the
	Prospectus Supplement.
	 
	4.4
	            
	L
	isting of Common
	Stock
	. The Company hereby agrees to use best efforts to maintain the
	listing or quotation of the Common Stock on the Trading Market on which it is
	currently listed, and concurrently with the Closing, the Company shall apply to
	list or quote all of the Shares and Warrant Shares on such Trading Market and
	promptly secure the listing of all of the Shares and Warrant Shares on such
	Trading Market. The Company further agrees, if the Company applies to have the
	Common Stock traded on any other Trading Market, it will then include in such
	application all of the Shares and Warrant Shares, and will take such other
	action as is necessary to cause all of the Shares and Warrant Shares to be
	listed or quoted on such other Trading Market as promptly as
	possible.  The Company will then take all action reasonably necessary
	to continue the listing and trading of its Common Stock on a Trading Market and
	will comply in all respects with the Company’s reporting, filing and other
	obligations under the bylaws or rules of the Trading Market.
	 
	ARTICLE
	V.
	MISCELLANEOUS
	 
	5.1
	           
	Fees and
	Expenses
	.  Each party shall pay the fees and expenses of its
	advisers, counsel, accountants and other experts, if any, and all other expenses
	incurred by such party incident to the negotiation, preparation, execution,
	delivery and performance of this Agreement; provided, however, that the Company
	shall reimburse Selected Value Therapeutics GP, LLC for its reasonable expenses
	up to a maximum of $3,000, and agrees to reimburse the Purchasers for their
	financial advisory expenses equal to 5% of the aggregate purchase price of the
	Securities purchased pursuant to this Agreement.  The Company shall
	pay all Transfer Agent fees, stamp taxes and other taxes and duties levied in
	connection with the delivery of any Securities to the Purchasers.
	 
	 
	5.2
	           
	Entire
	Agreement
	.  The Transaction Documents, together with the
	exhibits and schedules thereto, the Prospectus and the Prospectus Supplement,
	contain the entire understanding of the parties with respect to the subject
	matter hereof and supersede all prior agreements and understandings, oral or
	written, with respect to such matters, which the parties acknowledge have been
	merged into such documents, exhibits and schedules.
	 
	5.3
	           
	Notices
	.  Any
	and all notices or other communications or deliveries required or permitted to
	be provided hereunder shall be in writing and shall be deemed given and
	effective on the earliest of: (a) the date of transmission, if such notice or
	communication is delivered via facsimile at the facsimile number set forth on
	the signature pages attached hereto prior to 5:30 p.m. (New York City time) on a
	Trading Day, (b) the next Trading Day after the date of transmission, if such
	notice or communication is delivered via facsimile at the facsimile number set
	forth on the signature pages attached hereto on a day that is not a Trading Day
	or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second
	(2
	nd
	)
	Trading Day following the date of mailing, if sent by U.S. nationally recognized
	overnight courier service or (d) upon actual receipt by the party to whom such
	notice is required to be given.  The address for such notices and
	communications shall be as set forth on the signature pages attached
	hereto.
	 
	5.4
	           
	Amendments;
	Waivers
	.  No provision of this Agreement may be waived,
	modified, supplemented or amended except in a written instrument signed, in the
	case of an amendment, by the Company and the Purchasers holding at least 67% in
	interest of the Shares then outstanding or, in the case of a waiver, by the
	party against whom enforcement of any such waived provision is
	sought.  No waiver of any default with respect to any provision,
	condition or requirement of this Agreement shall be deemed to be a continuing
	waiver in the future or a waiver of any subsequent default or a waiver of any
	other provision, condition or requirement hereof, nor shall any delay or
	omission of any party to exercise any right hereunder in any manner impair the
	exercise of any such right.
	 
	5.5
	           
	Headings
	.  The
	headings herein are for convenience only, do not constitute a part of this
	Agreement and shall not be deemed to limit or affect any of the provisions
	hereof.
	 
	5.6
	           
	Successors and
	Assigns
	.  This Agreement shall be binding upon and inure to the
	benefit of the parties and their successors and permitted
	assigns.  The Company may not assign this Agreement or any rights or
	obligations hereunder without the prior written consent of each Purchaser (other
	than by merger).  Any Purchaser may assign any or all of its rights
	under this Agreement to any Person to whom such Purchaser assigns or transfers
	any Securities, provided that such transferee agrees in writing to be bound,
	with respect to the transferred Securities, by the provisions of the Transaction
	Documents that apply to the “Purchasers.”
	 
	5.7
	           
	No Third-Party
	Beneficiaries
	.  This Agreement is intended for the benefit of
	the parties hereto and their respective successors and permitted assigns and is
	not for the benefit of, nor may any provision hereof be enforced by, any other
	Person.
	 
	5.8
	           
	Governing
	Law
	.  All questions concerning the construction, validity,
	enforcement and interpretation of the Transaction Documents shall be governed by
	and construed and enforced in accordance with the internal laws of the State of
	New York, without regard to the principles of conflicts of law
	thereof.
	 
	5.9
	           
	Survival
	.  The
	representations and warranties contained herein shall survive the Closing and
	the delivery of the Securities.
	 
	5.10
	         
	Execution
	.  This
	Agreement may be executed in two or more counterparts, all of which when taken
	together shall be considered one and the same agreement and shall become
	effective when counterparts have been signed by each party and delivered to the
	other party, it being understood that both parties need not sign the same
	counterpart.  In the event that any signature is delivered by
	facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
	signature shall create a valid and binding obligation of the party executing (or
	on whose behalf such signature is executed) with the same force and effect as if
	such facsimile or “.pdf” signature page were an original thereof.
	 
	 
	5.11
	           
	Severability
	.  If
	any term, provision, covenant or restriction of this Agreement is held by a
	court of competent jurisdiction to be invalid, illegal, void or unenforceable,
	the remainder of the terms, provisions, covenants and restrictions set forth
	herein shall remain in full force and effect and shall in no way be affected,
	impaired or invalidated, and the parties hereto shall use their commercially
	reasonable efforts to find and employ an alternative means to achieve the same
	or substantially the same result as that contemplated by such term, provision,
	covenant or restriction. It is hereby stipulated and declared to be the
	intention of the parties that they would have executed the remaining terms,
	provisions, covenants and restrictions without including any of such that may be
	hereafter declared invalid, illegal, void or unenforceable.
	 
	5.12
	           
	Replacement of
	Securities
	.  If any certificate or instrument evidencing any
	Securities is mutilated, lost, stolen or destroyed, the Company shall issue or
	cause to be issued in exchange and substitution for and upon cancellation
	thereof (in the case of mutilation), or in lieu of and substitution therefor, a
	new certificate or instrument, but only upon receipt of evidence reasonably
	satisfactory to the Company of such loss, theft or destruction.  The
	applicant for a new certificate or instrument under such circumstances shall
	also pay any reasonable third-party costs (including customary indemnity)
	associated with the issuance of such replacement Securities.
	 
	5.13
	           
	Independent Nature of
	Purchasers’ Obligations and Rights
	.  The obligations of each
	Purchaser under any Transaction Document are several and not joint with the
	obligations of any other Purchaser, and no Purchaser shall be responsible in any
	way for the performance or non-performance of the obligations of any other
	Purchaser under any Transaction Document.  Nothing contained herein or
	in any other Transaction Document, and no action taken by any Purchaser pursuant
	thereto, shall be deemed to constitute the Purchasers as a partnership, an
	association, a joint venture or any other kind of entity, or create a
	presumption that the Purchasers are in any way acting in concert or as a group
	with respect to such obligations or the transactions contemplated by the
	Transaction Documents.  Each Purchaser shall be entitled to
	independently protect and enforce its rights including, without limitation, the
	rights arising out of this Agreement or out of the other Transaction Documents,
	and it shall not be necessary for any other Purchaser to be joined as an
	additional party in any proceeding for such purpose.  The Company has
	elected to provide all Purchasers with the same terms and Transaction Documents
	for the convenience of the Company and not because it was required or requested
	to do so by any of the Purchasers.
	 
	5.14
	           
	Saturdays, Sundays,
	Holidays, etc.
	      If the last or appointed day
	for the taking of any action or the expiration of any right required or granted
	herein shall not be a Business Day, then such action may be taken or such right
	may be exercised on the next succeeding Business Day.
	 
	5.15
	           
	Construction
	. The
	parties agree that each of them and/or their respective counsel has reviewed and
	had an opportunity to revise the Transaction Documents and, therefore, the
	normal rule of construction to the effect that any ambiguities are to be
	resolved against the drafting party shall not be employed in the interpretation
	of the Transaction Documents or any amendments hereto. In addition, each and
	every reference to share prices and shares of Common Stock in any Transaction
	Document shall be subject to adjustment for reverse and forward stock splits,
	stock dividends, stock combinations and other similar transactions of the Common
	Stock that occur after the date of this Agreement.
	 
	5.16
	           
	WAIVER OF JURY
	TRIAL
	.  
	IN ANY ACTION, SUIT, OR
	PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE
	PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY
	APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
	WAIVES FOREVER TRIAL BY JURY.
	 
	 
	IN
	WITNESS WHEREOF, the parties hereto have caused this Securities Purchase
	Agreement to be duly executed by their respective authorized signatories as of
	the date first indicated above.
| 
 
	ENTREMED,
	INC.
 
	 
 
 | 
	 
 | 
| 
 
	By:_____________________________
 
 | 
	 
 | 
| 
 
	     
	Name:  Michael M. Tarnow
 
 | 
	 
 | 
| 
 
	     
	Title:    Executive Chairman
 
 | 
	 
 | 
| 
	 
 | 
	 
 | 
| 
 
	Address
	for notice:
 
 | 
	 
 | 
| 
	 
 | 
	 
 | 
| 
 
	9640
	Medical Center Drive
 
 | 
	 
 | 
| 
 
	Rockville,
	Maryland 20850
 
 | 
	 
 | 
| 
 
	Attention:   General
	Counsel & Secretary
 
 | 
	 
 | 
| 
 
	Facsimile:  240.864.2601
 
 | 
	 
 | 
| 
	 
 | 
	 
 | 
| 
 
	With
	a copy to (which shall not constitute notice):
 
 | 
	 
 | 
| 
 
	 
 
	Richard
	E. Baltz
 
	Arnold
	& Porter LLP
 
	555
	12
	th
	St., N.W.
 
	Washington,
	D.C.  20004
 
	Facsimile:  202.942.5999
 
 | 
	 
 | 
 
	[REMAINDER
	OF PAGE INTENTIONALLY LEFT BLANK
	SIGNATURE
	PAGE FOR PURCHASER FOLLOWS]
	 
	[PURCHASER
	SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]
	IN
	WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement
	to be duly executed by their respective authorized signatories as of the date
	first indicated above.
	 
	Name of
	Purchaser: ________________________________________________________
	 
	Signature
	of Authorized Signatory of Purchaser:
	_________________________________
	 
	Name of
	Authorized Signatory:
	_______________________________________________
	 
	Title of
	Authorized Signatory:
	________________________________________________
	 
	Facsimile
	Number of Authorized Signatory:
	__________________________________________
	 
	Address
	for Notice of Purchaser:
	Address
	for Delivery of Securities (Warrants) for Purchaser (if not same as address for
	notice):
	Subscription
	Amount: $_________________
	Shares:
	_________________
	Warrant
	Shares: __________________
	Brokerage
	Account Name and Account Number (for delivery of shares via DWAC):
	___________________________________________
	Name of
	Brokerage Firm or Agent To Receive Shares
	______________________
	Account
	Name
	______________________
	Account
	No.
	______________________
	DTC
	No.
	 
	FOR
	IMMEDIATE RELEASE:
	September
	8, 2010
	7:00 a.m.
	ET
	ENTREMED
	SECURES $5.1 MILLION IN REGISTERED
	DIRECT OFFERING AND ENTERS INTO AGREEMENT
	FOR
	RIGHTS TO LICENSE ENMD-2076 IN CHINA
	Financing
	Extends Cash Runway Through 2011 and Sets Stage for Expanding ENMD-2076 Clinical
	Development Program
	ROCKVILLE, MD
	– September 8,
	2010 – EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company
	focused on the development of ENMD-2076, its proprietary Aurora A/angiogenic
	kinase inhibitor for the treatment of cancer, today announced that on September
	7, 2010 it entered into a securities purchase agreement with a group of
	strategic investors for gross proceeds of approximately $5.1
	million.  The Company expects to complete the offering on or about
	September 8, 2010.  The financing will provide capital to fund
	operations through 2011 and enable the Company to move forward with expansion of
	development plans for ENMD-2076, which is currently in Phase 1 and Phase 2
	clinical trials.  The ongoing Phase 2 trial of ENMD-2076 in ovarian
	cancer patients continues on track and the Company looks forward to the
	presentation of data early in 2011.
	The
	investor group was led by Tak W. Mak, Ph.D., Director of The Campbell Family
	Institute for Cancer Research, and includes scientific advisors to EntreMed as
	well as experienced investors who have expertise both in oncology drug
	development and in drug development in the China markets. Concurrent with the
	execution of the securities purchase agreement, EntreMed entered into a rights
	agreement with Selected Value Therapeutics I, LLC (SVT) pursuant to which SVT
	has an option to exercise, on behalf of the investors, certain license,
	development and commercialization rights for ENMD-2076 in China, enabling the
	Company to leverage the experience and access that these investors have in this
	growing market.  If the option is exercised, EntreMed will be entitled
	to receive development milestone payments and royalties on future product sales
	within the geographic market. The option is exercisable at any time until
	December 31, 2011.
	“We
	worked with Selected Value Therapeutics to develop an innovative financing
	structure that accomplishes our financing goals with minimum dilution to our
	current investors,” said Michael M. Tarnow, Executive Chairman of
	EntreMed.  “The financing extends our cash runway through
	2011.  We are on track to complete our current Phase 2 ovarian cancer
	study and, based on the results from our Phase 1 studies, will move forward with
	our plans for expansion into additional clinical trials in other
	indications.  We view both the investment in the Company and the
	option to participate in the clinical development of the compound in China as a
	vote of confidence in the potential of ENMD-2076.”
 
	Dr. Tak
	W. Mak, a scientific advisor to EntreMed and a co-founder of Miikana
	Therapeutics, Inc. which was later acquired by EntreMed in 2006, added, “I have
	been involved with ENMD-2076 since its discovery by Miikana.  We look
	forward to EntreMed’s further development of this compound and are encouraged by
	its potential to improve the lives of cancer patients in the U.S. and
	abroad.”
	Terms
	of the Transaction
	 An
	aggregate of 1,886,662 shares of EntreMed’s common stock and warrants to
	purchase an aggregate of 377,327 shares of its common stock will be issued
	pursuant to the securities purchase agreement.  The shares of common
	stock and warrants were offered in units consisting of one share of common stock
	and 0.20 warrants to purchase one share of common stock at a price of $2.70 per
	unit to a group of accredited investors.  The common stock purchase
	price represents the consolidated closing bid price of EntreMed’s common stock
	on September 7, 2010.  The warrants have a term of three years and an
	exercise price of $2.825.
	Net
	proceeds from the offering will be approximately $4.7 million after deducting
	fees and estimated offering expenses payable by EntreMed.  In
	connection with the financing, the investor group was offered the right to
	designate one director to EntreMed’s Board of Directors, and the director
	nominee, if selected, will be identified by SVT and submitted to EntreMed for
	approval and election to the Company’s Board of Directors.
	The
	securities described above are being offered through a prospectus supplement and
	accompanying base prospectus pursuant to a registration statement, previously
	filed and declared effective by the Securities and Exchange Commission
	(SEC).  The prospectus supplement related to the offering will be
	filed with the SEC.  Ferghana Partners acted as financial advisor to
	EntreMed for these transactions.  Copies of the final prospectus supplement
	and accompanying base prospectus can be obtained from EntreMed or at the SEC’s
	website at
	www.sec.gov
	.
	This
	press release does not and shall not constitute an offer to sell or the
	solicitation of an offer to buy any of the securities, nor shall there be any
	sale of the securities in any state or jurisdiction in which such offer,
	solicitation or sale would be unlawful prior to registration or qualification
	under the securities laws of any state.
	About
	EntreMed
	EntreMed,
	Inc. is a clinical-stage pharmaceutical company committed to developing
	ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of
	cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in
	ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma,
	and leukemia.  Additional information about EntreMed is available on
	the Company’s web site at www.entremed.com and in various filings with the
	Securities and Exchange Commission.
	Forward
	Looking Statements
	This
	release contains forward-looking statements within the meaning of the Private
	Securities Litigation Reform Act with respect to the outlook for expectations
	for future financial or business performance, strategies, expectations and
	goals. Forward-looking statements are subject to numerous assumptions, risks and
	uncertainties, which change over time.  Forward-looking statements speak
	only as of the date they are made, and no duty to update forward-looking
	statements is assumed. Actual results could differ materially from those
	currently anticipated due to a number of factors, including those set forth in
	Securities and Exchange Commission filings under "Risk Factors," including
	 the risk that we may be unable to continue as a going concern as a result
	of our inability to raise sufficient capital for our operational needs; the
	possibility that we may be delisted from trading on the Nasdaq Capital Market;
	the volatility of our common stock; risks relating to the need for additional
	capital and the uncertainty of securing additional funding on favorable terms;
	the failure to consummate a transaction to monetize the royalty stream for any
	reason, including our inability to obtain the required third-party consents;
	declines in actual sales of Thalomid
	®
	resulting in reduced revenues; risks associated with the Company’s
	product candidates; the early-stage products under development; results in
	preclinical models are not necessarily indicative of clinical results;
	uncertainties relating to preclinical and clinical trials, including delays to
	the commencement of such trials; success in the clinical development of any
	products; dependence on third parties; future capital needs; and risks relating
	to the commercialization, if any, of the Company's proposed products (such as
	marketing, safety, regulatory, patent, product liability, supply, competition
	and other risks). 
	Contact:
	Ginny
	Dunn
	Associate
	Director
	Corporate
	Communications & Investor Relations
	240-864-2643
	###